Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Bonello covers the Healthcare sector, focusing on stocks such as GeneDx Holdings, Natera, and Guardant Health. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ...

This report describes and explains the liquid biopsy for cancer diagnostics market and covers 2019-2024, termed the historic ...

Craig-Hallum analyst William Bonello maintained a Buy rating on Navitas Semiconductor (NVTS – Research Report) today. The company’s shares ...

The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.

Colorectal cancer (CRC), which affects the colon or rectum, represents a significant public health challenge. It ranks as the ...

Exact Sciences appears to be leveraging a broadly similar approach to other leaders in the space, like Guardant Health, Natera (NTRA) and GRAIL (GRAL). Real-world performance will ultimately ...